The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

References

• Lopetuso LR, Petito V, Scaldaferri F, et al. Gut microbiota modulation and mucosal immunity: focus on Rifaximin. Mini Rev Med Chem. 2015;16(3):179–185. PubMed PMID: 26643042.
   PubMed Web of Science ®Google Scholar
• Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. World J Gastroenterol. 2015 Aug 7;21(29):8787–8803. PubMed PMID: 26269668; PubMed Central PMCID: PMC4528021.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635–1638. PubMed PMID: 15831718; PubMed Central PMCID: PMC1395357.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780–13785. PubMed PMID: 17699621; PubMed Central PMCID: PMC1959459.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Scaldaferri F, Petito V, et al. The role of antibiotics in gut microbiota modulation: the eubiotic effects of Rifaximin. Dig Dis. 2016;34(3):269–278. PubMed PMID: 27027301.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015 Jan;37(1):47–55. PubMed PMID: 25420450; PubMed Central PMCID: PMC4281375.
   PubMed Web of Science ®Google Scholar
• Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995 Mar;49(3):467–484. PubMed PMID: 7774516.
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014 Mar 12;15(3):382–392. PubMed PMID: 24629344; PubMed Central PMCID: PMC4059512.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006 Feb;55(2):205–211. PubMed PMID: 16188921; PubMed Central PMCID: PMC1856500.
   PubMed Web of Science ®Google Scholar
• Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010 Dec;139(6):1844–1854 e1. PubMed PMID: 20816835.
   PubMed Web of Science ®Google Scholar
• Tong M, Li X, Wegener Parfrey L, et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS ONE. 2013;8(11):e80702. PubMed PMID: 24260458; PubMed Central PMCID: PMC3834335.
   PubMed Web of Science ®Google Scholar
• Gophna U, Sommerfeld K, Gophna S, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol. 2006 Nov;44(11):4136–4141. PubMed PMID: 16988016; PubMed Central PMCID: PMC1698347.
   PubMed Web of Science ®Google Scholar
• Scanlan PD, Shanahan F, O’Mahony C, et al. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn’s disease. J Clin Microbiol. 2006 Nov;44(11):3980–3988. PubMed PMID: 16988018; PubMed Central PMCID: PMC1698357.
   PubMed Web of Science ®Google Scholar
• Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008 Jun 12;3(6):417–427. PubMed PMID: 18541218; PubMed Central PMCID: PMC2872787.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731–16736. PubMed PMID: 18936492; PubMed Central PMCID: PMC2575488.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014 Feb;52(2):398–406. PubMed PMID: 24478468; PubMed Central PMCID: PMC3911339.
   PubMed Web of Science ®Google Scholar
• Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol. 2008 Jul;298(5–6):463–472. PubMed PMID: 17897884.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Plamondon S, Hart A, et al. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol. 2008 Oct;46(10):3510–3513. PubMed PMID: 18701655; PubMed Central PMCID: PMC2566070.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991 Sep 28;338(8770):771–774. PubMed PMID: 1681159.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Hur C, Juillerat P, et al. Strategies for the prevention of postoperative recurrence in Crohn’s disease: results of a decision analysis. Am J Gastroenterol. 2011 Nov;106(11):2009–2017. PubMed PMID: 21788991.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119–124. PubMed PMID: 23128233; PubMed Central PMCID: PMC3491803.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390–407. PubMed PMID: 16819502.
   PubMedGoogle Scholar
• Graham DB, Xavier RJ. From genetics of inflammatory bowel disease towards mechanistic insights. Trends Immunol. 2013 Aug;34(8):371–378. PubMed PMID: 23639549; PubMed Central PMCID: PMC3735683.
   PubMed Web of Science ®Google Scholar
• Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013 Oct;62(10):1505–1510. PubMed PMID: 24037875; PubMed Central PMCID: PMC3822528.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014 May;146(6):1489–1499. PubMed PMID: 24560869; PubMed Central PMCID: PMC4034132.
   PubMed Web of Science ®Google Scholar
• Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis. 2009 Jun;22(3):292–301. PubMed PMID: 19352175; PubMed Central PMCID: PMC2763597.
   PubMed Web of Science ®Google Scholar
• Dogan B, Scherl E, Bosworth B, et al. Multidrug resistance is common in Escherichia coli associated with ileal Crohn’s disease. Inflamm Bowel Dis. 2013 Jan;19(1):141–150. PubMed PMID: 22508665.
   PubMed Web of Science ®Google Scholar
• Barnich N, Darfeuille-Michaud AA-I. Escherichia coli and Crohn’s disease. Curr Opin Gastroenterol. 2007 Jan;23(1):16–20. PubMed PMID: 17133079.
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007 Sep;7(9):607–613. PubMed PMID: 17714674.
   PubMed Web of Science ®Google Scholar
• Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology. 2007 Jun;132(7):2313–2319. PubMed PMID: 17570206.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Okayasu I, Tokoi S, et al. Bacterial invasion into the colonic mucosa in ulcerative colitis. J Gastroenterol Hepatol. 1993 Jan-Feb;8(1):116–118. PubMed PMID: 8439657.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002 Aug;17(8):849–853. PubMed PMID: 12164960.
   PubMed Web of Science ®Google Scholar
• Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005 Apr;128(4):891–906. PubMed PMID: 15825073.
   PubMed Web of Science ®Google Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011 May;60(5):631–637. PubMed PMID: 21209126.
   PubMed Web of Science ®Google Scholar
• Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011 Jan;17(1):179–184. PubMed PMID: 20839241; PubMed Central PMCID: PMC3834564.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004 Nov;53(11):1658–1664. PubMed PMID: 15479689; PubMed Central PMCID: PMC1774270.
   PubMed Web of Science ®Google Scholar
• Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell. 2010 Jun 25;141(7):1135–1145. PubMed PMID: 20602997; PubMed Central PMCID: PMC2908380.
   PubMed Web of Science ®Google Scholar
• Dey N, Soergel DA, Repo S, et al. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol. 2013 Aug 22;13:131. PubMed PMID: 23964800; PubMed Central PMCID: PMC3848607.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. PubMed PMID: 15855748 Chemotherapy. 2005;51(Suppl 1):36–66.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. PubMed PMID: 16498249 Digestion. 2006;73(Suppl 1):13–27.
   PubMed Web of Science ®Google Scholar
• Blandizzi C, Viscomi GC, Marzo A, et al. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014 Jul;85:39–44. PubMed PMID: 24836868.
   PubMed Web of Science ®Google Scholar
• DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016 Jan;43(Suppl 1):3–10. PubMed PMID: 26618921.
   PubMed Web of Science ®Google Scholar
• Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002 Jun;14(3):290–295. PubMed PMID: 12120885.
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010 Dec;65(12):2556–2565. PubMed PMID: 20852272.
   PubMed Web of Science ®Google Scholar
• Biancone L, Vernia P, Agostini D, et al. Effect of rifaximin on intestinal bacterial overgrowth in Crohn’s disease as assessed by the H2-Glucose breath test. Curr Med Res Opin. 2000;16(1):14–20. PubMed PMID: 16422030.
   PubMed Web of Science ®Google Scholar
• Balzan S, De Almeida Quadros C, De Cleva R, et al. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 2007 Apr;22(4):464–471. PubMed PMID: 17376034.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042. PubMed PMID: 23565181; PubMed Central PMCID: PMC3615021.
   PubMed Web of Science ®Google Scholar
• Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012 Jul;10(7):815–818. PubMed PMID: 22391344.
   PubMed Web of Science ®Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013 May;58(5):949–955. PubMed PMID: 23333527; PubMed Central PMCID: PMC3936319.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gerardi V, Pecere S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015 Nov 21 ;21(43):12322–12333. PubMed PMID: 26604640; PubMed Central PMCID: PMC4649116.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zou L, Jagavelu K, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012 Apr;56(4):893–899. PubMed PMID: 22173161; PubMed Central PMCID: PMC3307873.
   PubMed Web of Science ®Google Scholar
• Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity. J Antibiot. 2014 Sep;67(9):667–670. Tokyo. PubMed PMID: 25095806.
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M 3rd. et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014 Feb;146(2):484–96 e4. PubMed PMID: 24161699; PubMed Central PMCID: PMC3939606.
   PubMed Web of Science ®Google Scholar
• Labro MT. Anti-inflammatory activity of ansamycins. Expert Rev Anti Infect Ther. 2005 Feb;3(1):91–103. PubMed PMID: 15757460.
   PubMedGoogle Scholar
• Cianci R, Frosali S, Pagliari D, et al. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin. J Immunol Res. 2014;2014:696812. PubMed PMID: 25133198; PubMed Central PMCID: PMC4124847.
   PubMed Web of Science ®Google Scholar
• Brown EL, Xue Q, Jiang ZD, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother. 2010 Jan;54(1):388–396. PubMed PMID: 19858255; PubMed Central PMCID: PMC2798526.
   PubMed Web of Science ®Google Scholar
• Debbia EA, Maioli E, Roveta S, et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008 Apr;20(2):186–194. PubMed PMID: 18467244.
   PubMed Web of Science ®Google Scholar
• Bauerl C, Llopis M, Antolin M, et al. Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa. Genes Nutr. 2013 Mar;8(2):165–180. PubMed PMID: 22669626; PubMed Central PMCID: PMC3575885.
   PubMed Web of Science ®Google Scholar
• Menozzi A, Dall’Aglio M, Quintavalla F, et al. Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. BMC Vet Res. 2016 Oct 6;12(1):217. 10.1186/s12917–016–0851–0. PubMed PMID: 27716258; PubMed Central PMCID: PMC5053129.
   PubMedGoogle Scholar
• Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):246–256. PubMed PMID: 12592101.
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Theocharis S, Patsouris E, et al. Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr Drug Metab. 2013 Mar;14(3):341–350. PubMed PMID: 23237007.
   PubMed Web of Science ®Google Scholar
• Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010 Oct;335(1):32–41. PubMed PMID: 20627999; PubMed Central PMCID: PMC2957776.
   PubMed Web of Science ®Google Scholar
• Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015 Mar;13(1):105–120. PubMed PMID: 25595930; PubMed Central PMCID: PMCPMC4364996.
   PubMedGoogle Scholar
• Shen B. Acute and chronic pouchitis–pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol. 2012 Apr 17;9(6):323–333. PubMed PMID: 22508158.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016 Jan;43(Suppl 1):27–36. PubMed PMID: 26618923.
   PubMed Web of Science ®Google Scholar
• Kale-Pradhan PB, Zhao JJ, Palmer JR, et al. The role of antimicrobials in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):281–288. PubMed PMID: 23445237.
   PubMed Web of Science ®Google Scholar
• Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn’s disease. World J Gastroenterol. 2013 Feb 7;19(5):648–653. PubMed PMID: 23429474; PubMed Central PMCID: PMC3574590.
   PubMed Web of Science ®Google Scholar
• Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014 Feb;63(2):292–299. PubMed PMID: 23525574.
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):661–673. PubMed PMID: 21407187.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999 Jun;44(6):1220–1221. PubMed PMID: 10389700.
   PubMed Web of Science ®Google Scholar
• Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: an open label study. Gastroenterology. 2002;122:434.
   Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res Clin Exp. 2004 May;65(3):292–296. PubMed PMID: 24672084; PubMed Central PMCID: PMC3964535.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999 Jun;13(6):713–718. PubMed PMID: 10383499.
   PubMed Web of Science ®Google Scholar
• Muniyappa P, Gulati R, Mohr F, et al. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):400–404. PubMed PMID: 19668011.
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010 Feb 15;50(4):473–480. PubMed PMID: 20067425.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006 Dec;28(12):1983–1988. PubMed PMID: 17296455.
   PubMed Web of Science ®Google Scholar
• Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn’s disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des. 2010;16(33): 3684–3698. PubMed PMID: 21143147.
   PubMed Web of Science ®Google Scholar
• Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr Med Res Opin. 2005 Aug;21(8):1165–1169. PubMed PMID: 16083525.
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117–1125. PubMed PMID: 16611272.
   PubMed Web of Science ®Google Scholar
• Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn’s disease activity. Dig Dis Sci. 2010 Apr;55(4):1079–1084. PubMed PMID: 20112064.
   PubMed Web of Science ®Google Scholar
• Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: A randomized controlled study vs mesalamine. Gastroenterology. 2000;118(4):A781.
   Web of Science ®Google Scholar
• Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology. 2012 Mar;142(3):473–481 e4. PubMed PMID: 22155172.
   PubMed Web of Science ®Google Scholar
• Jigaranu AO, Nedelciuc O, Blaj A, et al. Is rifaximin effective in maintaining remission in Crohn’s disease? Dig Dis. 2014;32(4):378–383. PubMed PMID: 24969283.
   PubMed Web of Science ®Google Scholar
• Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol. 2011 Nov 14;17(42):4643–4646. PubMed PMID: 22180705; PubMed Central PMCID: PMC3237300.
   PubMed Web of Science ®Google Scholar
• Kumar J, Newton AMJ. Rifaximin – chitosan nanoparticles for inflammatory bowel Disease (IBD). PubMed PMID: 28034350 Recent Pat Inflamm Allergy Drug Discov. 2017;11(1):41–52.
   PubMed Web of Science ®Google Scholar